Pipeline

A pipeline of powerful possibilities.

Our strategy for value creation involves developing a combination therapy that includes antivirals and immunomodulators to provide a finite, curative treatment for people with chronic HBV. 

Arbutus Powerful Pipeline

cHBV Program

PHASE 1

PHASE 2

PHASE 3

Imdusiran (AB-729)

RNAi Therapeutic (Subcutaneous)

 

 

 

Imdusiran + Peg-IFNa-2a + NA IM-PROVE I

 

 

 

 

 

 

Imdusiran + vaccine + NA +/- nivolumab IM-PROVE II

 

 

 

 

 

 

AB-101

PD-L1 Inhibitor (Oral)

 

 

 

AB-101 in healthy subjects & cHBV patients AB-101-001

 

 

 

 

 

 

All Arbutus clinical trials are conducted in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice

Suppress Reduce Boost

HBV

Learn about our three-pronged Suppress, Reduce, Boost approach to HBV.

Discover our HBV assets